Latham & Watkins Advises Rayner on Investment from CVC Capital Partners

London corporate team represents UK’s leading ophthalmology business in the transaction.

June 29, 2021

Latham & Watkins advised Rayner and Phoenix Equity Partners on the sale of a majority interest to CVC Capital Partners VIII for an undisclosed amount.

Rayner is a manufacturer and developer of innovative intraocular lenses (IOLs) and associated pharmaceuticals. Rayner’s products deliver sight-restorative implants and treatments to patients during cataract and refractive surgeries. Rayner makes these and other products available to patients in over 80 countries, through its subsidiaries and distribution networks, to improve the eyesight of more than 300,000 patients per year.

The transaction is expected to close in Q3 2021, subject to customary closing conditions and receipt of required regulatory approvals.

The Latham team was led by London corporate partners Robbie McLaren and Farah O’Brien, with associates Gillian Bourke and Róisín Mbonu.

 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.